Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STOPAPE: Withholding Anticoagulation for Subsegmental Pulmonary Embolism
NCT04727437Phase 3Unknown
- Sponsor
- University of Birmingham
- Start
- Apr 2021
- Primary completion
- Jul 2023
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in Subsegmental pulmonary embolism (SSPE), sponsored by University of Birmingham. Primary endpoint: Composite of recurrent venous thromboembolism and clinically relevant bleeding at 3 months. Status: unknown.
02
Conditions
Subsegmental pulmonary embolism (SSPE)
Beyond the preview
Go deeper on NCT04727437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04727437.